Displaying drugs 5301 - 5325 of 5332 in total
N-{2,2-DIFLUORO-2-[(2R)-PIPERIDIN-2-YL]ETHYL}-2-[2-(1H-1,2,4-TRIAZOL-1-YL)BENZYL][1,3]OXAZOLO[4,5-C]PYRIDIN-4-AMINE
Experimental
Matched Name: … N-{2,2-DIFLUORO-2-[(2R)-PIPERIDIN-2-YL]ETHYL}-2-[2-(1H-1,2,4-TRIAZOL-1-YL)BENZYL][1,3]OXAZOLO[4,5-C]PYRIDIN …
Matched Iupac: … N-{2,2-difluoro-2-[(2R)-piperidin-2-yl]ethyl}-2-{[2-(1H-1,2,4-triazol-1-yl)phenyl]methyl}-[1,3]oxazolo …
Matched Iupac: … N-{2,2-difluoro-2-[(2R)-piperidin-2-yl]ethyl}-2-{[2-(1H-1,2,4-triazol-1-yl)phenyl]methyl}-[1,3]oxazolo …
N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOXAZIN-4-YL]ETHYL}ACETAMIDE
Experimental
Matched Name: … N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOXAZIN-4-YL]ETHYL …
Matched Iupac: … N-{2-[6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-4-yl]ethyl …
Matched Iupac: … N-{2-[6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-4-yl]ethyl …
Carisoprodol
Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications . This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with...
Approved
Matched Synonyms: … (±)-2-methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate ... N-isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamate ... 2-methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate …
Matched Description: … acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and ... itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with both aspirin and …
Matched Mixtures name: … Carisoprodol and Aspirin ... Carisoprodol and Aspirin ... Carisoprodol and Aspirin …
Matched Products: … Carisoprodol Tablets, USP, 350 mg …
Matched Description: … acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and ... itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with both aspirin and …
Matched Mixtures name: … Carisoprodol and Aspirin ... Carisoprodol and Aspirin ... Carisoprodol and Aspirin …
Matched Products: … Carisoprodol Tablets, USP, 350 mg …
Efmarodocokin alfa
Efmarodocokin alfa is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
Investigational
Matched Synonyms: … >P(158)), CH2(N67>G(227)))-(147-377), DIMER (156-156':159-159')-BISDISULFIDE, PRODUCED IN CHO CELLS, ... HUMAN INTERLEUKIN 22 (1-146), FUSED TO HUMAN IMMUNOGLOBULIN HEAVY CONSTANT GAMMA 4 (CH1(97-98), H(S10 …
Matched Description: … Efmarodocokin alfa is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and ... Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia). …
Matched Description: … Efmarodocokin alfa is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and ... Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia). …
(2R,3R,4S,5R,6E)-3,4,5-Trihydroxy-N-[(3S,6R)-6-hydroxy-2-oxo-3-azepanyl]-2-methoxy-8,8-dimethyl-6-nonenamide
Experimental
Matched Name: … (2R,3R,4S,5R,6E)-3,4,5-Trihydroxy-N-[(3S,6R)-6-hydroxy-2-oxo-3-azepanyl]-2-methoxy-8,8-dimethyl-6-nonenamide …
Matched Iupac: … (2R,3R,4S,5R,6E)-3,4,5-trihydroxy-N-[(3S,6R)-6-hydroxy-2-oxoazepan-3-yl]-2-methoxy-8,8-dimethylnon-6- …
Matched Iupac: … (2R,3R,4S,5R,6E)-3,4,5-trihydroxy-N-[(3S,6R)-6-hydroxy-2-oxoazepan-3-yl]-2-methoxy-8,8-dimethylnon-6- …
N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOTHIAZIN-4-YL]ETHYL}ACETAMIDE
Experimental
Matched Name: … N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOTHIAZIN-4-YL]ETHYL …
Matched Iupac: … N-{2-[6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-4-yl]ethyl …
Matched Iupac: … N-{2-[6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-4-yl]ethyl …
2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-3-METHYL-BUTYRIC ACID
Experimental
Matched Name: … 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-3-METHYL-BUTYRIC …
Matched Iupac: … (2S)-2-{[4-(2-{2-amino-4-oxo-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-5-yl}ethyl)phenyl]formamido}-3-methylbutanoic …
Matched Iupac: … (2S)-2-{[4-(2-{2-amino-4-oxo-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-5-yl}ethyl)phenyl]formamido}-3-methylbutanoic …
3-{[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol-2-one
Experimental
Matched Name: … 3-{[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol …
Matched Iupac: … 5-({[(3Z)-5-(1,3-oxazol-5-yl)-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}amino)-1,3-dihydro-2lambda6 …
Matched Iupac: … 5-({[(3Z)-5-(1,3-oxazol-5-yl)-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}amino)-1,3-dihydro-2lambda6 …
(1S,7S,8S,8AR)-1,2,3,7,8,8A-HEXAHYDRO-7-METHYL-8-[2-[(2R,4R)-TETRAHYDRO-4-HY DROXY-6-OXO-2H-PYRAN-2-YL]ETHYL]-1-NAPHTHALENOL
Experimental
Matched Name: … ]ETHYL]-1-NAPHTHALENOL ... (1S,7S,8S,8AR)-1,2,3,7,8,8A-HEXAHYDRO-7-METHYL-8-[2-[(2R,4R)-TETRAHYDRO-4-HY DROXY-6-OXO-2H-PYRAN-2-YL …
Matched Iupac: … (4R,6S)-6-{2-[(1S,2S,8S,8aR)-8-hydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]ethyl}-4-hydroxyoxan …
Matched Iupac: … (4R,6S)-6-{2-[(1S,2S,8S,8aR)-8-hydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]ethyl}-4-hydroxyoxan …
(2R)-2-[(1R)-1-[[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-2-oxoethyl]-5-methylidene-2H-1,3-thiazine-4-carboxylic acid
Experimental
Matched Name: … (2R)-2-[(1R)-1-[[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-2-oxoethyl]-5-methylidene ... -2H-1,3-thiazine-4-carboxylic acid …
Matched Iupac: … (2R)-2-[(1R)-1-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-oxoethyl]-5-methylidene ... -5,6-dihydro-2H-1,3-thiazine-4-carboxylic acid …
Matched Iupac: … (2R)-2-[(1R)-1-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-oxoethyl]-5-methylidene ... -5,6-dihydro-2H-1,3-thiazine-4-carboxylic acid …
2-{(9as)-9a-[(1s)-1-Hydroxyethyl]-2,7-Dimethyl-9a,10-Dihydro-5h-Pyrimido[4,5-D][1,3]Thiazolo[3,2-a]Pyrimidin-8-Yl}Ethyl Trihydrogen Diphosphate
Experimental
Matched Name: … 2-{(9as)-9a-[(1s)-1-Hydroxyethyl]-2,7-Dimethyl-9a,10-Dihydro-5h-Pyrimido[4,5-D][1,3]Thiazolo[3,2-a]Pyrimidin …
Matched Iupac: … {[hydroxy({2-[(3S)-3-[(1S)-1-hydroxyethyl]-6,12-dimethyl-4-thia-2,7,11,13-tetraazatricyclo[7.4.0.0^{3,7 ... }]trideca-1(13),5,9,11-tetraen-5-yl]ethoxy})phosphoryl]oxy}phosphonic acid …
Matched Iupac: … {[hydroxy({2-[(3S)-3-[(1S)-1-hydroxyethyl]-6,12-dimethyl-4-thia-2,7,11,13-tetraazatricyclo[7.4.0.0^{3,7 ... }]trideca-1(13),5,9,11-tetraen-5-yl]ethoxy})phosphoryl]oxy}phosphonic acid …
(2R)-4-[(8R)-8-METHYL-2-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[1,5-A]PYRAZIN-7(8H)-YL]-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE
Experimental
Matched Name: … (2R)-4-[(8R)-8-METHYL-2-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[1,5-A]PYRAZIN-7(8H)-YL]-4-OXO-1- …
Matched Iupac: … (3R)-3-amino-1-[(8R)-8-methyl-2-(trifluoromethyl)-5H,6H,7H,8H-[1,2,4]triazolo[1,5-a]pyrazin-7-yl]-4-( ... 2,4,5-trifluorophenyl)butan-1-one …
Matched Iupac: … (3R)-3-amino-1-[(8R)-8-methyl-2-(trifluoromethyl)-5H,6H,7H,8H-[1,2,4]triazolo[1,5-a]pyrazin-7-yl]-4-( ... 2,4,5-trifluorophenyl)butan-1-one …
Furosemide
Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It...
Approved
Vet approved
Matched Description: … Furosemide has a fast onset and short duration of action and has been used safely and effectively in ... both pediatric and adult patients. ... various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and …
Matched Mixtures name: … SEMİTONE 100/20 MG FILM TABLET, 30 ADET ... SEMİTONE 50/20 MG FILM TABLET, 30 ADET ... SEMİTONE 100/20 MG FILM TABLET, 10 ADET …
Matched Salts name: … Furosemide sodium …
Matched Categories: … Sulfur Compounds ... Sodium Potassium Chloride Symporter Inhibitors ... furosemide and potassium ... furosemide and potassium-sparing agents ... High-Ceiling Diuretics and Potassium-Sparing Agents …
Matched Products: … LASIX LONG 30 ... Lasix retard 30 mg Kapseln ... FUROSEMID 125 1A PHARMA …
Matched Mixtures name: … SEMİTONE 100/20 MG FILM TABLET, 30 ADET ... SEMİTONE 50/20 MG FILM TABLET, 30 ADET ... SEMİTONE 100/20 MG FILM TABLET, 10 ADET …
Matched Salts name: … Furosemide sodium …
Matched Categories: … Sulfur Compounds ... Sodium Potassium Chloride Symporter Inhibitors ... furosemide and potassium ... furosemide and potassium-sparing agents ... High-Ceiling Diuretics and Potassium-Sparing Agents …
Matched Products: … LASIX LONG 30 ... Lasix retard 30 mg Kapseln ... FUROSEMID 125 1A PHARMA …
N-[(E)-3-[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]prop-2-enyl]-2,3-dihydroxy-5-nitrobenzamide
Experimental
Matched Name: … N-[(E)-3-[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]prop-2-enyl]-2,3-dihydroxy-5-nitrobenzamide …
Matched Iupac: … N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]prop-2-en-1-yl]-2,3-dihydroxy …
Matched Iupac: … N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]prop-2-en-1-yl]-2,3-dihydroxy …
(4aS,4bR,10bS,12aS)-12a-methyl-1,3-dioxo-2-(pyridin-3-ylmethyl)-1,2,3,4,4a,4b,5,6,10b,11,12,12a-dodecahydronaphtho[2,1-f]isoquinolin-8-yl sulfamate
Experimental
Matched Name: … (4aS,4bR,10bS,12aS)-12a-methyl-1,3-dioxo-2-(pyridin-3-ylmethyl)-1,2,3,4,4a,4b,5,6,10b,11,12,12a-dodecahydronaphtho …
Matched Iupac: … (4aS,4bR,10bS,12aS)-12a-methyl-1,3-dioxo-2-[(pyridin-3-yl)methyl]-1H,2H,3H,4H,4aH,4bH,5H,6H,10bH,11H, ... 12H,12aH-naphtho[2,1-f]isoquinolin-8-yl sulfamate …
Matched Iupac: … (4aS,4bR,10bS,12aS)-12a-methyl-1,3-dioxo-2-[(pyridin-3-yl)methyl]-1H,2H,3H,4H,4aH,4bH,5H,6H,10bH,11H, ... 12H,12aH-naphtho[2,1-f]isoquinolin-8-yl sulfamate …
AB-22
Investigational
Matched Synonyms: … N-(2-chloro-6-propoxypyridin-4-yl)-2-(2-hydroxyethyl)-2-(4-isopropyl-1,3-dimethyl-1h-pyrazolo(3,4-b)pyridin ... N-(2-chloro-6-propoxypyridin-4-yl)-2-(2-hydroxyethyl)-2-(4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin ... (3,4-b)pyridin-6-yl)-2-(2-hydroxyethyl)- …
Matched Iupac: … 1-(2-chloro-6-propoxypyridin-4-yl)-3-{[1,3-dimethyl-4-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl](2 …
Matched Iupac: … 1-(2-chloro-6-propoxypyridin-4-yl)-3-{[1,3-dimethyl-4-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl](2 …
3-(5-Amino-7-oxo-3,7-dihydro-2H-[1,2,3]triazolo[4,5-d]pyrimidin-2-yl)-N-(2-{[2-(hydroxymethyl)phenyl]sulfanyl}benzyl)benzamide
Experimental
Matched Name: … 3-(5-Amino-7-oxo-3,7-dihydro-2H-[1,2,3]triazolo[4,5-d]pyrimidin-2-yl)-N-(2-{[2-(hydroxymethyl)phenyl] …
Matched Iupac: … 3-{5-amino-7-oxo-2H,3H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-2-yl}-N-[(2-{[2-(hydroxymethyl)phenyl]sulfanyl …
Matched Iupac: … 3-{5-amino-7-oxo-2H,3H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-2-yl}-N-[(2-{[2-(hydroxymethyl)phenyl]sulfanyl …
(5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
Experimental
Matched Name: … (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA ... [A]PHENANTHREN-3-ONE …
Matched Iupac: … (1S,3aS,3bR,5aS,9aS,9bS,11aR)-11a-{2-[(3,5-difluorophenyl)methoxy]ethyl}-1-hydroxy-9a-methyl-hexadecahydro ... -1H-cyclopenta[a]phenanthren-7-one …
Matched Iupac: … (1S,3aS,3bR,5aS,9aS,9bS,11aR)-11a-{2-[(3,5-difluorophenyl)methoxy]ethyl}-1-hydroxy-9a-methyl-hexadecahydro ... -1H-cyclopenta[a]phenanthren-7-one …
(2R,4S)-2-[(1R)-1-{[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2-oxoethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
Experimental
Matched Name: … (2R,4S)-2-[(1R)-1-{[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2-oxoethyl]-5,5-dimethyl ... -1,3-thiazolidine-4-carboxylic acid …
Matched Iupac: … (2R,4S)-2-[(1R)-1-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-oxoethyl]-5,5-dimethyl ... -1,3-thiazolidine-4-carboxylic acid …
Matched Iupac: … (2R,4S)-2-[(1R)-1-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-oxoethyl]-5,5-dimethyl ... -1,3-thiazolidine-4-carboxylic acid …
3-(4-Amino-2-Tert-Butyl-5-Methyl-Phenylsulfanyl)-6-Cyclopentyl-4-Hydroxy-6-[2-(4-Hydroxy-Phenyl)-Ethyl]-5,6-Dihydro-Pyran-2-One
Experimental
Matched Name: … 3-(4-Amino-2-Tert-Butyl-5-Methyl-Phenylsulfanyl)-6-Cyclopentyl-4-Hydroxy-6-[2-(4-Hydroxy-Phenyl)-Ethyl …
Matched Iupac: … (6S)-3-[(4-amino-2-tert-butyl-5-methylphenyl)sulfanyl]-6-cyclopentyl-4-hydroxy-6-[2-(4-hydroxyphenyl) …
Matched Iupac: … (6S)-3-[(4-amino-2-tert-butyl-5-methylphenyl)sulfanyl]-6-cyclopentyl-4-hydroxy-6-[2-(4-hydroxyphenyl) …
1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z)
Experimental
Matched Name: … 1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL ... )-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z) …
Matched Iupac: … (1R,3S,5Z)-5-{2-[(1S,3aS,4E,7aS)-1-(5-hydroxy-5-methylhexa-1,3-diyn-1-yl)-7a-methyl-octahydro-1H-inden ... -4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol …
Matched Iupac: … (1R,3S,5Z)-5-{2-[(1S,3aS,4E,7aS)-1-(5-hydroxy-5-methylhexa-1,3-diyn-1-yl)-7a-methyl-octahydro-1H-inden ... -4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol …
Tofersen
Tofersen is under an intrathecally administered antisense oligonucleotide targeting the mutated SOD1 gene that causes amyotrophic lateral sclerosis (ALS). Although there were various causes of ALS, 2% of ALS cases are due to SOD1 mutations, with more than 200 SOD1 mutations documented.[A259028,A259033] Tofersen was granted accelerated approval from the FDA...
Approved
Investigational
Matched Synonyms: … Antisense Oligonucleotide Inhibitor Of The Expression Of Superoxide Dismutase 1 Gene …
Matched Description: … [A259023] However, it could potentially be due to the short timeframe of tofersen treatment, and more ... [L46133] Tofersen demonstrated efficacy in reducing the concentration of SOD1 in CSF and of neurofilament ... Continual FDA approval is contingent on clinical benefits from ongoing trials, particularly the Phase 3 …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Matched Description: … [A259023] However, it could potentially be due to the short timeframe of tofersen treatment, and more ... [L46133] Tofersen demonstrated efficacy in reducing the concentration of SOD1 in CSF and of neurofilament ... Continual FDA approval is contingent on clinical benefits from ongoing trials, particularly the Phase 3 …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Inbakicept
Inbakicept is a dimeric human IL-15 receptor α (IL-15Rα) sushi domain/human IgG1 Fc fusion protein. It is one of the active ingredients in Anktiva, a combination product also containing nogapendekin alfa, where a single inbakicept is complexed with two nogapendekin alfa components. This combination product was approved by the FDA...
Investigational
Matched Synonyms: … ), CH3 (191-2 ... INTERLEUKIN 15 RECEPTOR .ALPHA. ... INTERLEUKIN 15 RECEPTOR SUBUNIT ALPHA (HUMAN IL15R.ALPHA.) (1-65)-PEPTIDE (SUSHI DOMAIN-CONTAINING) FUSION …
Matched Description: … the activation and proliferation of natural killer cells and CD8+ memory T cells, which also synergistically ... 75% of all bladder tumours, is commonly treated with transurethral resection of the bladder tumour and ... Inbakicept is a dimeric human IL-15 receptor α (IL-15Rα) sushi domain/human IgG1 Fc fusion protein. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Interleukin-15 ... Receptors, Interleukin-15 ... Experimental Unapproved Treatments for COVID-19 …
Matched Description: … the activation and proliferation of natural killer cells and CD8+ memory T cells, which also synergistically ... 75% of all bladder tumours, is commonly treated with transurethral resection of the bladder tumour and ... Inbakicept is a dimeric human IL-15 receptor α (IL-15Rα) sushi domain/human IgG1 Fc fusion protein. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Interleukin-15 ... Receptors, Interleukin-15 ... Experimental Unapproved Treatments for COVID-19 …
Narsoplimab
Thrombotic microangiopathies (TMA), including thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome, are associated with injury and dysregulation of microvascular endothelium and platelets. Evidence increasingly points to a role for the complement system in TMA.[A241030, A241040] Mannan-associated lectin-binding serine protease-2 (MASP-2) is a major effector in the complement lectin pathway.[A241030,...
Investigational
Matched Synonyms: … PROTEIN-ASSOCIATED SERINE PROTEASE 2, EC=3.4.21.104) HUMAN MONOCLONAL ANTIBODY .GAMMA.4 HEAVY CHAIN (1- …
Matched Description: … uremic syndrome, are associated with injury and dysregulation of microvascular endothelium and platelets ... Thrombotic microangiopathies (TMA), including thrombotic thrombocytopenic purpura and atypical hemolytic ... consideration as a treatment for hematopoietic stem cell transplant-associated TMA (HSCT-TMA/TA-TMA) and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Description: … uremic syndrome, are associated with injury and dysregulation of microvascular endothelium and platelets ... Thrombotic microangiopathies (TMA), including thrombotic thrombocytopenic purpura and atypical hemolytic ... consideration as a treatment for hematopoietic stem cell transplant-associated TMA (HSCT-TMA/TA-TMA) and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Ethyl (2E)-4-({(2S)-2-[(N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-valyl)amino]-2-phenylacetyl}amino)-5-[(3S)-2-oxo-3-pyrrolidinyl]-2-pentenoate
Experimental
Matched Name: … )-2-oxo-3-pyrrolidinyl]-2-pentenoate ... Ethyl (2E)-4-({(2S)-2-[(N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-valyl)amino]-2-phenylacetyl}amino)-5-[(3S …
Matched Iupac: … [(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate ... ethyl (2E)-4-[(2S)-2-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-3-methylbutanamido]-2-phenylacetamido]-5- …
Matched Iupac: … [(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate ... ethyl (2E)-4-[(2S)-2-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-3-methylbutanamido]-2-phenylacetamido]-5- …
Displaying drugs 5301 - 5325 of 5332 in total